Asset Details
Do you wish to reserve the book?
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Do you wish to request the book?
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
2010
Overview
In this randomized trial involving patients with
Clostridium difficile
infection, treatment with monoclonal antibodies against
C. difficile
toxins A and B, in addition to metronidazole or vancomycin, reduced the rate of recurrence of infection, as compared with placebo (7% vs. 25%).
In patients with
C. difficile
infection, treatment with monoclonal antibodies against
C. difficile
toxins A and B, in addition to metronidazole or vancomycin, reduced the rate of recurrence of infection, as compared with placebo (7% vs. 25%).
During the past decade, there has been a striking increase in the prevalence of
Clostridium difficile
infection and in associated mortality in the United States, Canada, and Europe.
1
–
5
The widespread use of broad-spectrum antibiotics places patients at risk for
C. difficile
diarrhea or colitis and has changed the epidemiology of
C. difficile
infection. This has been characterized by the emergence of a hypervirulent strain of
C. difficile
(BI/NAP1/027) and an increasing risk of treatment failure and recurrent infection.
1
,
6
–
14
We developed one fully human monoclonal antibody targeted against
C. difficile
toxin A (CDA1) and a second against toxin . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Antitoxins - adverse effects
/ Antitoxins - therapeutic use
/ Bacterial Proteins - antagonists & inhibitors
/ Bacterial Proteins - immunology
/ Bacterial Toxins - antagonists & inhibitors
/ Bacterial Toxins - immunology
/ Biological and medical sciences
/ Clostridium Infections - drug therapy
/ Diarrhea
/ Enterocolitis, Pseudomembranous - drug therapy
/ Enterotoxins - antagonists & inhibitors
/ Enzymes
/ Female
/ Humans
/ Male
/ Metronidazole - therapeutic use
/ Patients
/ Toxins
